FDA Approval Expected for Glaxo’s Migraine Drug

OPEN MINDS The Behavioral Health & Social Service Industry Analyst Industry News The U.S. Food And Drug Administration (FDA) is soon expected to approve Imigran, a drug developed by Glaxo Holdings PLC for the treatment of migraine headaches. Imigran is one of two drugs to be introduced by Glaxo (the other being ondansetron for chemotherapy) based on serotonin research. The first such drug introduced was Eli Lilly & Company’s Prozac, according to a report by Michale Waldholz, "Brain Explorers Use Chemical Messengers To Design New Drug," that appeared in the October 25, 1991 (page Al, A6) of The . . .